Actively Recruiting
A Study to Assess Anktiva in Patients With Long Covid-19.
Led by ImmunityBio, Inc. · Updated on 2026-05-11
20
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
CONDITIONS
Official Title
A Study to Assess Anktiva in Patients With Long Covid-19.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to less than 70 years.
- Enrolled or willing to enroll in the UCSF Long-term Impact of Infection with Novel Coronavirus study.
- History of at least one confirmed SARS-CoV-2 infection by positive nucleic acid amplification test or antigen rapid test.
- Clinical evidence of Long COVID with at least 2 new or worsened symptoms present for at least 60 days, impacting quality of life.
- At least 90 days have passed since the most recent suspected or confirmed SARS-CoV-2 infection.
- Not currently hospitalized.
- Body mass index between 18 and 50 kg/m2 at screening.
- In stable health as assessed by the Investigator within 28 days prior to screening.
- For males with female partners of childbearing potential, agreement to use effective contraception and other related conditions.
- For females engaging with male partners, not pregnant or breastfeeding and agreement to contraception and pregnancy testing requirements.
- Willingness and ability to comply with study protocol, including transportation and visit attendance.
- Written informed consent obtained from participant or legal representative.
You will not qualify if you...
- Received SARS-CoV-2 antiviral or monoclonal antibody therapy within 30 days before planned treatment or plans to receive before study end.
- Plans to receive any SARS-CoV-2 vaccine or booster within 14 days before treatment or before follow-up.
- History of autoimmune diseases such as celiac disease, rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
- Active cardiovascular disease including recent myocardial infarction, coronary artery bypass, heart failure with reduced ejection fraction, or pulmonary arterial hypertension.
- Stroke within 3 months prior to treatment.
- Active infection other than SARS-CoV-2 requiring treatment within 14 days before treatment.
- Major surgery within 3 months before treatment or planned surgery during the first 75 days after treatment.
- Unplanned hospitalization longer than 24 hours within 28 days prior to screening.
- Active or prior Hepatitis B infection.
- Active Hepatitis C infection.
- Laboratory abnormalities including low neutrophil count, platelet count, hemoglobin, or kidney function.
- Known or suspected HIV infection.
- End stage kidney disease requiring dialysis.
- History of diabetes requiring systemic medication or insulin.
- Severe liver impairment (Child-Pugh Class C).
- Moderate or severe immunocompromise including recent cancer treatment or transplant.
- Prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome or dysautonomia unrelated to SARS-CoV-2 infection.
- Allergies to intervention components or history of severe allergic reactions.
- Recent participation in another clinical trial with investigational products within 28 days.
- Current alcohol or illicit drug use that precludes participation.
- Any condition or abnormality that compromises participant safety or data quality as judged by the Investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California - San Francisco
San Francisco, California, United States, 94110
Actively Recruiting
Research Team
K
Kayleigh Russell
CONTACT
J
Jayson Garmizo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here